

solifenacin (Vesicare®)

(No. 129/04)

Yamanouchi

Summary of Advice

08 November 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a full submission.

Solifenacin is not recommended for use within NHS Scotland for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Solifenacin is effective in reducing symptoms associated with overactive bladder including frequency, urgency and incontinence. It is associated with adverse events typical of antimuscarinic agents used in this condition. Comparison with other treatments is limited to one placebo-controlled trial involving tolterodine as an active control, and this trial was not designed to detect differences between active treatments. The economic case for using the product was not demonstrated.

Professor David H Lawson
Chairman